Ascentage pushes APG-2449 ovarian cancer trial readout to May 2027
The Phase 1 study of Ascentage's ALK/ROS1/FAK inhibitor in platinum-resistant ovarian cancer added 40 patients and moved its completion date back a year, with no data yet posted.
Executive Summary
- Ascentage Pharma Group Inc. moved the completion date for its Phase 1 trial of APG-2449 in platinum-resistant ovarian cancer back by a year and expanded planned enrollment, resetting when safety and early-activity data will be available.
- The study is designed to define a tolerable dose and characterize treatment-related toxicity for APG-2449 alone or combined with pegylated liposomal doxorubicin, not to demonstrate efficacy.
- APG-2449 sits in a field of ALK-targeted small molecules built almost entirely around non-small cell lung cancer; its ovarian cancer application is a readthrough into a tumor type where ALK inhibition has not been established, and where no other Phase 1 program targeting ALK is running in this indication.
- Ascentage is running APG-2449 in a second, separate Phase 1 trial across other tumors, and its broader portfolio shows a completion rate in the range typical of clinical-stage oncology sponsors.
The registry change
Ascentage Pharma Group Inc. filed an update to NCT06687070 on July 21, 2026 that pushed the primary completion date for its Phase 1 study of APG-2449 from May 1, 2026 to May 1, 2027, a 365-day delay. The same filing raised the anticipated enrollment target from 50 to 90 patients. The trial's overall completion date, covering long-term follow-up beyond the primary endpoint, moved out further still, to May 1, 2028. NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STNCT06687070
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial is built to answer
The study tests APG-2449, an oral small molecule inhibiting ALK, ROS1 and FAK, given alone or combined with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer or advanced tumors. Its primary endpoints are dose-limiting toxicity assessed over the first 28 days and the rate of treatment-related adverse events graded by NCI-CTCAE version 5.0 over one year. This is a dose-finding and tolerability study, open-label with two arms and no randomized comparator, so its information value is what dose and combination prove tolerable, not a claim about tumor response. NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STNCT06687070
Enrollment in context
The enrollment increase from 50 to 90 patients falls within the routine range the operational model uses to flag Phase 1 trials, and Phase 1 enrollment increases are excluded from that model's alarm threshold altogether. The trial has logged four registry events since its November 2024 filing: initial submission, a shift from not-yet-recruiting to recruiting in February 2025, and the July 2026 enrollment and timeline update. That is a moderate rate of protocol change for a trial of this age, consistent with a study still building its cohort rather than one in distress. NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STNCT06687070
The competitive position
APG-2449 sits among nine direct comparators targeting ALK with small-molecule inhibitors in active clinical testing, including InxMed's ifebemtinib, Nuvalent's zidesamtinib and NVL-655, and Turning Point Therapeutics' repotrectinib, but nearly all of that activity runs in non-small cell lung cancer, where ALK rearrangements are an established biomarker. Ovarian cancer is not a validated setting for ALK inhibition, and no other Phase 1 industry trial pairs an ALK-targeted agent with this indication. Ascentage is also running APG-2449 in a separate Phase 1 study across tumors including non-small cell lung cancer, mesothelioma, esophageal cancer and ovarian cancer, giving the molecule two live early-phase readouts feeding the same asset. Approved ALK inhibitors including lorlatinib, crizotinib, ceritinib, alectinib and brigatinib are cleared for ALK-positive non-small cell lung cancer, not for ovarian cancer, so none stands as an approved option in this trial's indication. For a Phase 1 safety study entering an indication without a validated ALK-driven biology, the bar this program has to clear is a tolerability profile without dose-limiting toxicities that block dose escalation, and an early hint of tumor activity durable enough to justify moving into a larger cohort in platinum-resistant disease.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.